CRISPR Therapeutics, a leading gene editing company, has reported significant developments in its financial and operational activities as of June 30, 2024. Financially, the company has issued 1.5 million common shares under the 2021 ATM at an average price of $139.28 per share, resulting in aggregate proceeds of $212.4 million, net of equity issuance costs. Additionally, CRISPR Therapeutics entered into a registered direct offering in February 2024, selling approximately $280.0 million of its common shares to institutional investors. The company's net loss for the three months ended June 30, 2024, was $126.4 million, a notable increase from the $77.7 million loss in the same period in 2023. In terms of business development, CRISPR Therapeutics has made strides with its CRISPR/Cas9-based therapeutics, including the landmark approval of CASGEVY, the first CRISPR-based...Show More

CRISPR Therapeutics, a leading gene editing company, has reported significant developments in its financial and operational activities as of June 30, 2024. Financially, the company has issued 1.5 million common shares under the 2021 ATM at an average price of $139.28 per share, resulting in aggregate proceeds of $212.4 million, net of equity issuance costs. Additionally, CRISPR Therapeutics entered into a registered direct offering in February 2024, selling approximately $280.0 million of its common shares to institutional investors. The company's net loss for the three months ended June 30, 2024, was $126.4 million, a notable increase from the $77.7 million loss in the same period in 2023. In terms of business development, CRISPR Therapeutics has made strides with its CRISPR/Cas9-based therapeutics, including the landmark approval of CASGEVY, the first CRISPR-based therapy, in 2023. The company has a robust portfolio of therapeutic programs across hemoglobinopathies, immuno-oncology, autoimmune, in vivo approaches, and type 1 diabetes. Looking ahead, CRISPR Therapeutics plans to continue advancing its therapeutic programs, with a focus on expanding the number of patients who can benefit from its gene editing technologies. The company is also innovating with its CRISPR-X research team to develop next-generation editing modalities and has established strategic partnerships to broaden its therapeutic applications and accelerate program development.